Charité-ko ikertzaileekin lankidetzan egindako argitalpenak (1)

2022

  1. Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden

    European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 8, Núm. 1, pp. 31-38